简体中文
EnglishWhat is InVitria and what does the company provide?
Updated
InVitria is a manufacturer of recombinant, animal-origin-free proteins used in cell culture, biomanufacturing, and final formulation. The company produces its proteins with a proprietary ExpressTec® rice grain–based expression platform, which avoids animal- or human-derived components. Its products are used in FDA- and EMA-approved biologics, including the first FDA-approved vaccine containing recombinant human albumin (rHSA), and are made at an ISO 9001:2015 certified facility in Kansas, USA.
What InVitria makes
InVitria's catalog is built around recombinant proteins and the cell culture products formulated from them. All are described as chemically defined and free of animal or human components.
| Category | Examples |
|---|---|
| Recombinant proteins | Recombinant albumin (rHSA), transferrin, lysozyme, interleukins |
| Cell culture components | Insulin-transferrin supplements |
| Complete media | Blood-free complete media |
The catalog is available as a downloadable PDF covering product specifications, formats, and applications.
How the products are made
The differentiator is the expression system. Instead of plasma sourcing or mammalian cell expression, InVitria uses ExpressTec®, a rice grain–based recombinant platform. The stated consequences are:
- No animal or human components in the production chain, which removes a common source of batch variability.
- Consistency and scalability — the company cites metric-ton capacity and global distribution.
- Reduced contamination risk compared with serum- or blood-derived inputs.
- Lower carbon footprint relative to animal-derived sourcing, per the company's sustainability positioning.
For process developers, the practical appeal is replacing serum or plasma-derived albumin and transferrin with a chemically defined recombinant equivalent, which simplifies regulatory documentation around adventitious agents.
Who uses it
InVitria lists seven application areas:
- Gene therapy
- Cell therapy
- Vaccine production
- T-cell immunotherapy
- Antibody production
- Final formulation
- Medical devices
The company reports 1,000+ active customers, 300+ customer clinical programs, and distribution in 40+ countries.
When InVitria is a fit
InVitria is worth evaluating if your process needs a blood-free or animal-origin-free albumin, transferrin, or supplement, particularly if you are preparing for clinical or commercial stages where raw-material traceability and batch consistency matter. If your workflow already specifies a serum-derived component and no regulatory or yield pressure exists to change it, switching carries requalification cost. The company provides a knowledge base searchable by cell line or application, which is the fastest way to check whether a specific product is documented for your system.